Cost-Effectiveness Analysis of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Infection in High-Risk Late Preterm Infants in the Netherlands

Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.286
https://www.valueinhealthjournal.com/article/S1098-3015(13)02191-8/fulltext
Title : Cost-Effectiveness Analysis of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Infection in High-Risk Late Preterm Infants in the Netherlands
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02191-8&doi=10.1016/j.jval.2013.08.286
First page : A372
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 271
Categories :
Tags :
Regions :
ViH Article Tags :